{"created":"2023-05-15T16:33:32.574909+00:00","id":5814,"links":{},"metadata":{"_buckets":{"deposit":"ded64c88-f605-4727-bbbc-d51b43b0d208"},"_deposit":{"created_by":2,"id":"5814","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"5814"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00005814","sets":["8:9"]},"author_link":["24897","24899","24912","24906","24898","24908","24900","24901","24910","24902","24909","24911","24905","24904","24907","24903"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-09","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"502","bibliographicPageStart":"497","bibliographicVolumeNumber":"74","bibliographic_titles":[{"bibliographic_title":"Cancer Chemotherapy and Pharmacology"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Amrubicin is active in the treatment of extensive-disease small cell lung cancer (ED-SCLC), and carboplatin is an analogue of cisplatin with less non-hematological toxicity. Purpose: The purpose of this study was to determine the efficacy and toxicity of amrubicin and carboplatin combination chemotherapy for previously untreated patients with ED-SCLC. Patients and methods: Eligibility criteria were chemotherapy-naive ED-SCLC patients, performance status 0-1, age ?75, and adequate hematological, hepatic and renal function. Based on the phase I study, the patients received amrubicin 35 mg/m2 i.v. infusion on days 1, 2, and 3, and carboplatin AUC 5 i.v. infusion on day 1. Four cycles of chemotherapy were repeated every 3 weeks. Results: Thirty-five patients were enrolled, and 34 patients were eligible and assessable for response, toxicity, and survival. Patients' characteristics were as follows: male/female = 26/8; performance status 0/1 = 4/30; median age (range) = 64 (41-75); stage IV = 34. Evaluation of responses was 6 complete response, 21 partial response, and 7 stable disease (response rate 79.4 %, 95 % CI 63.6-88.5 %). Grade 3 and 4 leukopenia, neutropenia, and thrombocytopenia occurred in 59, 82, and 26 %, respectively. There were no treatment-related deaths or pneumonitis. Three patients experienced hypotension as an amrubicin infusion reaction. The median progression-free survival time was 6.5 months. The median overall survival time and 1-, 2-, and 3-year survival rates were 15.6 months, and 63, 28, and 7 %, respectively. Conclusions: Amrubicin and carboplatin were effective and tolerable as chemotherapy for previously untreated patients with ED-SCLC. Further investigation of amrubicin and carboplatin is warranted.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Cancer Chemotherapy and Pharmacology, 74(3), pp.497-502; 2014","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer Verlag"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1007/s00280-014-2527-4","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c 2014 Springer-Verlag."},{"subitem_rights":"The final publication is available at link.springer.com"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03445704","subitem_source_identifier_type":"ISSN"}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"14320843","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ikeda, Takaya"}],"nameIdentifiers":[{"nameIdentifier":"24897","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Fukuda, Minoru"}],"nameIdentifiers":[{"nameIdentifier":"24898","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nakamura, Yoichi"}],"nameIdentifiers":[{"nameIdentifier":"24899","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kinoshita, Akitoshi"}],"nameIdentifiers":[{"nameIdentifier":"24900","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Senju, Hiroaki"}],"nameIdentifiers":[{"nameIdentifier":"24901","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nakano, Hirofumi"}],"nameIdentifiers":[{"nameIdentifier":"24902","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kitazaki, Takeshi"}],"nameIdentifiers":[{"nameIdentifier":"24903","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ogawara, Daiki"}],"nameIdentifiers":[{"nameIdentifier":"24904","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Taniguchi, Hirokazu"}],"nameIdentifiers":[{"nameIdentifier":"24905","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Motoshima, Kohei"}],"nameIdentifiers":[{"nameIdentifier":"24906","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yamaguchi, Hiroyuki"}],"nameIdentifiers":[{"nameIdentifier":"24907","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nakatomi, Katsumi"}],"nameIdentifiers":[{"nameIdentifier":"24908","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Shimada, Midori"}],"nameIdentifiers":[{"nameIdentifier":"24909","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nagashima, Seiji"}],"nameIdentifiers":[{"nameIdentifier":"24910","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tsukamoto, Kazuhiro"}],"nameIdentifiers":[{"nameIdentifier":"24911","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kohno, Shigeru"}],"nameIdentifiers":[{"nameIdentifier":"24912","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-21"}],"displaytype":"detail","filename":"CCP74_497.pdf","filesize":[{"value":"161.4 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"CCP74_497.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/5814/files/CCP74_497.pdf"},"version_id":"d43bb49a-a244-4c26-a654-64aa6b1a8e33"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Amrubicin","subitem_subject_scheme":"Other"},{"subitem_subject":"Carboplatin","subitem_subject_scheme":"Other"},{"subitem_subject":"Phase II study","subitem_subject_scheme":"Other"},{"subitem_subject":"Small cell lung cancer","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer"}]},"item_type_id":"2","owner":"2","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2015-10-01"},"publish_date":"2015-10-01","publish_status":"0","recid":"5814","relation_version_is_last":true,"title":["A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T02:58:42.266253+00:00"}